@staaroc

staaroc has been a member of Linktree for 3 years and joined in February 2023. The social media accounts linked to from staaroc are: Facebook, Instagram, TikTok, YouTube, LinkedIn. Besides social media accounts, staaroc has populated their site with 2026 Voices of LGSOC Patient Survey, Founder Spotlight: Bailey Wolfe, Founder Spotlight: Bailey Wolfe on Why STAAR Began — and Why It Still Matters, Blog | Staaroc, Donate to STAAR, LGSOC Awareness Day—Sept. 9, Volunteer with STAAR, Share Your Story, LGSOC Video Library, Shop the STAAR store, Woman, 25, with ovarian cancer recalls symptoms that doctors dismissed: 'You’re fine', FDA approves first LGSOC treatment, Sips & Celebrations sign up, 4th Annual World Ovarian Cancer Coalition Impact Awards, Avutometinib and Defactinib May Benefit Some with LGSOC, STAAR’s fight for better outcomes, The Development and progression of low-grade serous ovarian carcinoma, Woman shares experience battling LGSOC, Tribute to Meredith Blake: Dec. 15, 1971 - July 15, 2024, Research Update on Recurrent Low-Grade Serous Ovarian Cancer - New York | SHARE Cancer Support, Car show at Wilkes University benefits STAAR, Doctors Dismissed My Pelvic Pain for Years, Endocrine study published in British Journal of Cancer, STAAR blog: Kate Middleton's Cancer Battle, Detection test for ovarian cancer being developed, Results of Global Patient Survey, Orphan Drug Designation Is Beacon of Hope, Verastem Oncology Receives Orphan Drug Designation, STAAR expands study into trametinib resistance at MD Anderson, STAAR funds combination drug trial, STAAR honored for Inspirational Collaborations, Low-Grade Serous Ovarian Cancer 2023 Update, LGSOC Patient Impact Survey Results, Patient-Centered Approaches to LGSOC, Everyday Health, NBC Chicago Health & Wellness report, Journal article: State of LGSOC Science, Let’s Talk About LGSOC, Share it Saturday: B.E.A.C.H., OC 360 LIVE: Dr. David Gershenson, What’s the Latest in Low-Grade Serous Ovarian Cancer?, Updated Results from Verastem clinical trial.